Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Monoclonal antibodies are widely used to treat non-infectious conditions but are costly. Vaccines could offer a cost-effective alternative but have been limited by sub-optimal T-cell stimulation and/or weak vaccine responses in recipients, for example, in elderly patients. We have previously shown that the repetitive structure of virus-like-particles (VLPs) can effectively bypass self-tolerance in therapeutic vaccines. Their efficacy could be increased even further by the incorporation of an epitope stimulating T cell help. However, the self-assembly and stability of VLPs from envelope monomer proteins is sensitive to geometry, rendering the incorporation of foreign epitopes difficult. We here show that it is possible to engineer VLPs derived from a non human-pathogenic plant virus to incorporate a powerful T-cell-stimulatory epitope derived from Tetanus toxoid. These VLPs (termed CMV TT) retain self-assembly as well as long-term stability. Since Th cell memory to Tetanus is near universal in humans, CMV TT-based vaccines can deliver robust antibody-responses even under limiting conditions. By way of proof of concept, we tested a range of such vaccines against chronic inflammatory conditions (model: psoriasis, antigen: interleukin-17), neurodegenerative (Alzheimer’s, β-amyloid), and allergic disease (cat allergy, Fel-d1), respectively. Vaccine responses were uniformly strong, selective, efficient in vivo, observed even in old mice, and employing low vaccine doses. In addition, randomly ascertained human blood cells were reactive to CMV TT-VLPs, confirming recognition of the incorporated Tetanus epitope. The CMV TT-VLP platform is adaptable to almost any antigen and its features and performance are ideally suited for the design of vaccines delivering enhanced responsiveness in aging populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“In terms of the so-called amyloid hypothesis, there is evidence that early dosing with antibodies specifically targeting N-terminal Aβ1–42 may be effective.(28) Clearly, frequent administration of antibodies over decades in patients without clinical symptoms would be impractical.”
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“Frames from each movie were aligned and averaged to produce drift-corrected micrographs.(27) Data are summarized in Table S1.”
Cited by
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
Self-citationBrune, K. D., & Howarth, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01432 · Cited by 161
“Though existing Catcher/Tag-VLNP platforms have not yet been thoroughly assessed for T cell responses, recent work has enhanced T cell induction based on co-delivered adjuvants (114), additional helper T-cell epitopes (115), or incorporating cell-permeable peptides (116).”
BackgroundThoms, F., Jennings, G. T., Maudrich, M., Vogel, M., Haas, S., Zeltins, A., Hofmann-Lehmann, R., Riond, B., Grossmann, J., Hunziker, P., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.01.050 · Cited by 69
“Thus our VLPs carry both pathogen-associated structural patterns and pathogen-associated molecular patterns, which renders them a suitable carrier platform for antigens by linking them to the surfaces of the VLPs.5-7 Recently, we have shown that vaccines based on CuMVTT are able to induce antibodies against IL-31 that…”
BackgroundMethodSelf-citationImmunization of Cats against Fel d 1 Results in Reduced Allergic Symptoms of Owners
Thoms, F., Haas, S., Erhart, A., Nett, C. S., Rüfenacht, S., Graf, N., Strods, A., Patil, G., Leenadevi, T., Fontaine, M. C., et al. (2020) · Viruses · doi:10.3390/v12030288 · Cited by 37
“The vaccine is based on a recombinantly expressed Fel d 1 protein covalently linked to a virus-like particle (VLP) derived from the Cucumber mosaic virus (CuMV) [37].”
BackgroundSelf-citationEngineering intramolecular adjuvants for next-generation vaccines
Wang, Y., Liao, W., Zhang, Z., Wang, T., Zhang, J., Zai, X., & Xu, J. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2026.100258
Metadata
- Authors
- Zeltins, A., West, J., Zabel, F., El Turabi, A., Balke, I., Haas, S., Maudrich, M., Storni, F., Engeroff, P., Jennings, G. T., Kotecha, A., Stuart, D. I., Foerster, J., & Bachmann, M. F.
- Venue
- npj Vaccines
- Published
- 2017-10-23
- Volume
- 2
- Issue
- 1
- Pages
- 30-30
- ISSN
- 2059-0105 (ISSN-L)
- OpenAlex
- W2763661741
- Cited by
- 104
- References
- 2
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy. https://app.cochat.ai/papers/10.1038/s41541-017-0030-8
- The paper
- Zeltins, A., West, J., Zabel, F., El Turabi, A., Balke, I., Haas, S., Maudrich, M., Storni, F., Engeroff, P., Jennings, G. T., Kotecha, A., Stuart, D. I., Foerster, J., & Bachmann, M. F. (2017). Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy. npj Vaccines. https://doi.org/10.1038/s41541-017-0030-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.